| Adjuvant hyperthermia for extremity melanomas |
| JR Oleson |
|
JCO Dec 1 1991: 2085–2087.
[PDF]
|
 |
| Immunotoxins: prospects and problems |
| J Mendelsohn |
|
JCO Dec 1 1991: 2088–2090.
[PDF]
|
|
|
Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group |
| |
L Hafstrom, CM Rudenstam, E Blomquist, C Ingvar, PE Jonsson, B Lagerlof, C Lindholm, U Ringborg, G Westman, and L Ostrup |
| |
JCO Dec 1 1991: 2091–2094.
[Abstract]
[PDF]
|
|
|
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer |
| |
LH Pai, MA Bookman, RF Ozols, RC Young, JW Smith, 2d, DL Longo, B Gould, A Frankel, EF McClay, and S Howell |
| |
JCO Dec 1 1991: 2095–2103.
[Abstract]
[PDF]
|
|
|
A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma |
| |
ET Creagan, DI Twito, SL Johansson, DJ Schaid, PS Johnson, MA Flaum, TR Buroker, LH Geeraerts, MH Veeder, and DH Gesme, Jr |
| |
JCO Dec 1 1991: 2104–2109.
[Abstract]
[PDF]
|
|
|
Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity |
| |
MA Caligiuri, C Murray, RJ Soiffer, TR Klumpp, M Seiden, K Cochran, C Cameron, C Ish, L Buchanan, and D Perillo |
| |
JCO Dec 1 1991: 2110–2119.
[Abstract]
[PDF]
|
|
|
Biologic effects of recombinant human interleukin-3 in vivo |
| |
A Lindemann, A Ganser, F Herrmann, J Frisch, G Seipelt, G Schulz, D Hoelzer, and R Mertelsmann |
| |
JCO Dec 1 1991: 2120–2127.
[Abstract]
[PDF]
|
|
|
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial |
| |
JA DeCaprio, RJ Mayer, R Gonin, and SG Arbuck |
| |
JCO Dec 1 1991: 2128–2133.
[Abstract]
[PDF]
|
|
|
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes |
| |
R Buzzoni, G Bonadonna, P Valagussa, and M Zambetti |
| |
JCO Dec 1 1991: 2134–2140.
[Abstract]
[PDF]
|
|
|
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer |
| |
DC Talbot, IE Smith, JL Mansi, I Judson, AH Calvert, and SE Ashley |
| |
JCO Dec 1 1991: 2141–2147.
[Abstract]
[PDF]
|
|
|
A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer |
| |
DJ Perez, VJ Harvey, BA Robinson, CH Atkinson, PJ Dady, AR Kirk, BD Evans, and PJ Chapman |
| |
JCO Dec 1 1991: 2148–2152.
[Abstract]
[PDF]
|
|
|
Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study |
| |
G Falkson, R Gelman, CI Falkson, J Glick, and J Harris |
| |
JCO Dec 1 1991: 2153–2161.
[Abstract]
[PDF]
|
|
|
A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study |
| |
W Heim, GL Wampler, JJ Lokich, HD Brereton, SJ Scialla, F LaLuna, JD Ahlgren, J Nevin, JG Fryer, and D Alt |
| |
JCO Dec 1 1991: 2162–2166.
[Abstract]
[PDF]
|
|
|
Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group |
| |
JA Ortega, MD Krailo, JE Haas, DR King, AR Ablin, JJ Quinn, J Feusner, JR Campbell, DA Lloyd, and J Cherlow |
| |
JCO Dec 1 1991: 2167–2176.
[Abstract]
[PDF]
|
|
|
Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report |
| |
A Suarez, H McDowell, P Niaudet, E Comoy, and F Flamant |
| |
JCO Dec 1 1991: 2177–2182.
[Abstract]
[PDF]
|
|
|
Impact of chromosomal translocations on prognosis in childhood acute lymphoblastic leukemia |
| |
CM Rubin, MM Le Beau, R Mick, MA Bitter, J Nachman, R Rudinsky, HJ Appel, E Morgan, CR Suarez, and HR Schumacher |
| |
JCO Dec 1 1991: 2183–2192.
[Abstract]
[PDF]
|
|
|
Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations |
| |
J Yahalom, J Ryu, DJ Straus, JJ Gaynor, J Myers, J Caravelli, BD Clarkson, and Z Fuks |
| |
JCO Dec 1 1991: 2193–2201.
[Abstract]
[PDF]
|
|
|
Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma |
| |
JW Sweetenham, GM Mead, and JM Whitehouse |
| |
JCO Dec 1 1991: 2202–2209.
[Abstract]
[PDF]
|
|
|
Phase I study of combination drug purging for autologous bone marrow transplantation |
| |
SD Rowley, CB Miller, S Piantadosi, JM Davis, GW Santos, and RJ Jones |
| |
JCO Dec 1 1991: 2210–2218.
[Abstract]
[PDF]
|
|
|
Mood and clinical status in patients with multiple myeloma |
| |
PM Silberfarb, KM Anderson, AC Rundle, JC Holland, MR Cooper, and OR McIntyre |
| |
JCO Dec 1 1991: 2219–2224.
[Abstract]
[PDF]
|
|
|
Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials |
| |
JA O'Shaughnessy, RE Wittes, G Burke, MA Friedman, JR Johnson, JE Niederhuber, ML Rothenberg, J Woodcock, BA Chabner, and R Temple |
| |
JCO Dec 1 1991: 2225–2232.
[Abstract]
[PDF]
|
|
| Place of double half-body irradiation in the treatment of multiple myeloma? |
| X Troussard and M Leporrier |
|
JCO Dec 1 1991: 2233–2235.
[PDF]
|
|
| Acquired immune deficiency syndrome-related Kaposi's sarcoma |
| SE Krown |
|
JCO Dec 1 1991: 2235–2237.
[PDF]
|
|
